Earnings Feed
Start Free
Home/Filings/4/0000914190-14-000014
4//SEC Filing

Arno Therapeutics, Inc 4

Accession 0000914190-14-000014

CIK 0001195116operating
View on SEC.govCompany Profile

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 4:24 PM ET

Size

19.6 KB

Accession

0000914190-14-000014

Insider Transaction Report

Form 4
Period: 2014-01-24
Arno Therapeutics, IncARNI
Zukiwski Alexander A
VP & Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2014-01-24+711,301→ 711,301 total
    Exercise: $2.90Exp: 2024-01-24→ Common Stock (711,301 underlying)
Holdings

  • Common Stock

    117,026

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-22→ Common Stock (109,375 underlying)
    109,375

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-11-04→ Common Stock (316,389 underlying)
    316,389

  • 2012 Series A Warrants (right to buy)

    Exercise: $2.40From: 2012-11-26Exp: 2017-11-26→ Common Stock (104,166 underlying)
    104,166

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (12,187 underlying)
    12,187

  • 2012 Series B Warrants (right to buy)

    Exercise: $2.40From: 2013-10-29Exp: 2014-10-31→ Common Stock (62,500 underlying)
    62,500

  • 2013 Series E Warrants (right to buy)

    Exercise: $2.40From: 2013-10-29Exp: 2014-10-31→ Common Stock (41,666 underlying)
    41,666

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2021-06-22→ Common Stock (55,736 underlying)
    55,736

  • Stock Option (right to buy)

    Exercise: $2.40Exp: 2023-01-14→ Common Stock (36,562 underlying)
    36,562

  • 2013 Series D Warrants (right to buy)

    Exercise: $4.00From: 2013-10-29Exp: 2018-10-29→ Common Stock (41,666 underlying)
    41,666
Footnotes (6)
  • [F1]25% vested on 6/22/12 and thereafter in 24 equal monthy installments.
  • [F2]On 6/22/2011, the Reporting Person was granted an option to purchase up to 109,375 shares of common stock of the Issuer. Up to 1/3 of the shares subject to the option may vest annually (or a pro rata portion thereof for a period of less than a full year) based on the achievement of cerain performance milestones as determined by the Board of Directors (the 'Board') of the Issuer. On 1/17/2012, the Board determined that options for the prorated period ending 12/31/2011 would vest in the maximum potential amount of 19,278 shares. On 1/14/2013, the Board determined that options for the period ending 12/31/2012 would vest in the maximum potential amount of 36,458 shares.
  • [F3]1/3 vested on 1/14/13 and thereafter will vest in 24 equal monthy installments, commencing 1/31/13.
  • [F4]On 1/14/13, the Reporting Person was granted an option to purchase up to 36,562 shares of common stock of the Issuer. 1/3 of the shares subject to the option were immediately vested and up to 1/2 of the remaining shares subject to the option may vest annually, based on the achievement of certain performance milestones as determined by the Board.
  • [F5]Vests in equal 36-monthly installments commencing 12/4/13.
  • [F6]Vests 25% on first anniversary date and thereafter will vest in 24 equal monthly installments.

Documents

1 file

Issuer

Arno Therapeutics, Inc

CIK 0001195116

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001195116

Filing Metadata

Form type
4
Filed
Jan 27, 7:00 PM ET
Accepted
Jan 28, 4:24 PM ET
Size
19.6 KB
View on SEC.gov